Detumomab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458275734

| image =

| type = mab

| mab_type = mab

| source = o

| target = B-lymphoma cell

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 145832-33-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 8Z3Q8X4UAD

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma.{{cite journal | title = International Nonproprietary Names (INN) for Pharmaceutical Substances. | journal = WHO Drug Information | volume = 7 | issue = 4 | date = 1993 | url = http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list70.pdf | archive-url = https://web.archive.org/web/20070614042528/http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list70.pdf | archive-date = 14 June 2007 }}{{cite journal | vauthors = Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK | title = Monoclonal Antibodies: A Review | journal = Current Clinical Pharmacology | volume = 13 | issue = 2 | pages = 85–99 | date = 2018 | pmid = 28799485 | doi = 10.2174/1574884712666170809124728 | s2cid = 27211386 }}